- $354.66m
- $771.38m
- $512.12m
- 62
- 57
- 95
- 82
Annual cashflow statement for Bioventus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.2 | 6.3 | 14.7 | 9.59 | -213 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 25.4 | 18 | 13.6 | 1.56 | 200 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.85 | -13.6 | 15.3 | -13.3 | -14.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 45.2 | 40.7 | 71.8 | 23 | -13.5 |
| Capital Expenditures | -2.56 | -2.34 | -4.09 | -7.37 | -10 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -3.54 | -5.57 | -16.4 | -276 | -106 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -6.1 | -7.91 | -20.5 | -284 | -116 |
| Financing Cash Flow Items | -7.85 | -9.5 | -19.6 | -2.24 | -3.37 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -13.3 | -11 | -29.6 | 273 | 62.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.7 | 21.7 | 22.3 | 12.4 | -67.4 |